Psilocybin May Relieve Chemotherapy Side Effects According to New Study

Psilocybin could offer a long-awaited preventative solution for chemotherapy-induced peripheral neuropathy, according to preclinical research highlighted by outlets including WELT.

A significant number of cancer patients suffer from the painful condition, which is characterized by the die-off of nerve endings in the extremities. It causes unpleasant tingling, sensory disturbances, motor weaknesses, and stabbing pain in the hands and feet. The toxicity of certain cancer-fighting medications damages the transport mechanisms of nerve cells, preventing essential metabolic components from reaching their destinations.

How Nerve Damage Disrupts Cancer Treatment

This nerve damage often creates severe clinical complications during cancer treatment. Neuropathy is unpredictable, sometimes emerging after long periods of successful therapy and forcing physicians to lower the dose of cancer drugs or halt treatment entirely. Because effective treatments for chemotherapy-induced peripheral neuropathy remain scarce, the medical community faces a persistent challenge in managing these debilitating side effects.

Preclinical Data from U.S. Mouse Models

To address this issue, a recent study conducted in the United States examined whether psilocybin could prevent nerve damage before it starts. Researchers used a mouse model to systematically demonstrate that administering psilocybin largely prevents the death of nerve cells caused by chemotherapy drugs.

The preclinical findings suggest the compound could protect nerves for extended periods, with some reports indicating protective effects lasting up to eight months, as noted by ad-hoc-news.de.

Pharmacology and Regulatory Realities

In nature, psilocybin occurs naturally in roughly 180 species of fungi, with the «spitzkegelige Kahlkopf» being particularly widespread in Central Europe. When consumed, the body converts psilocybin into psilocin, which interacts with serotonin in the brain to alter perception, thought patterns, and mood. While the substance remains strictly regulated or illegal in many jurisdictions, clinical use under strict supervision is permitted in specific settings, such as in clinics in Switzerland.

The Upcoming NeuroGuard Clinical Initiative

Additional research efforts are already underway to evaluate these neuroprotective properties further. A clinical initiative named the NeuroGuard study is scheduled to begin in November, according to ad-hoc-news.de and Biermann Medizin, aiming to investigate Psilocybin’s potential against chemotherapy side effects in greater detail.

As oncologists and researchers review the preclinical data, the medical community awaits human clinical trials to determine whether the promising protective effects observed in animal models will successfully translate to human patients undergoing cancer therapy.